-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Beijing, China and Durham, North Carolina, U.
Overall, among 837 outpatients with a high risk of clinical progression, BRII-196/BRII-198 reduced the risk of hospitalization and death by 78% compared with placebo
The BRII-196/BRII-198 ACTIV-2 study joint lead researcher, Teresa H.
These results were presented in the latest oral report at the 2021 American Infectious Disease Week (IDWeek) annual meeting on September 30, 2021
Eric S.
David Margolis, Vice President of Tengshengbo Pharmaceutical and Head of Infectious Disease Treatment, said: "The BRII-196/BRII-198 combination therapy has more and more positive data, including the consistent significant risk in patients at different stages of disease progression.
In addition, Tengshengbo Pharmaceutical also presented the results of the preclinical and phase 1 studies in the poster of Infectious Disease Week (IDWeek) in the United States
Based on these results and increasing evidence to support the use of the BRII-196/BRII-198 combination therapy, Tengshengbo Pharmaceutical plans to submit an emergency use authorization (EUA) application to the U.
Phase 3 of the ACTIV-2 trial was conducted in clinical trial centers around the world, including the United States, Brazil, South Africa, Mexico, Argentina, and the Philippines
About BRII-196 and BRII-198
BRII-196 and BRII-198 are non-competitive new severe acute respiratory syndrome virus 2 (SARS-CoV-2) monoclonal neutralizing antibodies obtained from patients with new coronavirus pneumonia (COVID-19) during the convalescence period.
New drug clinical trial applications for the BRII-196/BRII-198 combination therapy have been submitted to the U.
About ACTIV-2
The ACTIV-2 trial (NCT04518410) was supported by the National Institute of Allergy and Infectious Diseases (NIAID) under the National Institutes of Health (NIH) and sponsored by the AIDS Clinical Trial Group (ACTG) funded by NIAID
The ACTIV-2 main program adopts a randomized, double-blind, and controlled adaptive platform clinical trial design to evaluate the safety and effectiveness of therapeutic drugs for symptomatic non-hospital adult patients with new coronary disease
About Tengshengbo Pharmaceutical
Tengsheng Bo Yao Biotechnology Co.
